drugset / Trial / NCT01259141

The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

NCT01259141

Completed 208 enrolled Capital Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

Mycoplasma pneumoniae, an important pathogen of community acquired pneumonia,are becoming more and more resistant to macrolide. The study aim is to optimize anti-infection therapy.

Timeline

Start
2010-10
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 0.5 unknown
Subject Cefuroxime Small molecule 1.5 unknown
Subject Moxifloxacin Small molecule 0.4 unknown